Bristol-Myers Squibb (BMY) Misses Q2 EPS by 23c, Lowers Guidance
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $63.06 +0.35%
EPS Growth %: +5.5%
Financial Fact:
Net Sales: 4.92B
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +5.5%
Financial Fact:
Net Sales: 4.92B
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $1.75, $0.23 worse than the analyst estimate of $1.98. Revenue for the quarter came in at $11.2 billion versus the consensus estimate of $11.81 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2023 EPS of $7.35-$7.65, versus the consensus of $7.99.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb Co. (BMY) PT Raised to $82 at Piper Sandler
- Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
- Westinghouse said to seek over $50 billion valuation in planned IPO
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
